NCT07621783 Leucine-rich α2-glycoprotein Correlation With Clinical, Endoscopic and Histological Disease Activity of IBD in a EuRopean Context
| NCT ID | NCT07621783 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Imelda GI Clinical Research Center |
| Condition | Crohn Disease (CD) |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2026-05-01 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2026-05-01 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Prospectively study the correlation between Leucine-rich α2-glycoprotein (LRG) and clinical/endoscopic/histological disease activity in patients with inflammatory bowel disease (IBD) in Europe.
Eligibility Criteria
Inclusion Criteria: 1. ≥18 years 2. Patient with confirmed diagnosis of IBD 3. Patient with planned endoscopy (ileocolonoscopy for Crohn's disease (CD)/ulcerative colitis (UC) or sigmoidoscopy for UC) for the assessment of endoscopic disease activity according to routine practice 4. willing to provide informed consent Exclusion Criteria: 1. Patient with IBD unspecified 2. Patient with ileo- or colostomy 3. Patient with total colectomy 4. Women that are pregnant
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07621783 clinical trial?
This trial is open to participants of all sexes, aged 16 Years or older, studying Crohn Disease (CD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07621783 currently recruiting?
Yes, NCT07621783 is actively recruiting participants. Contact the research team at peter.bossuyt@imelda.be for enrollment information.
Where is the NCT07621783 trial being conducted?
This trial is being conducted at Bonheiden, Belgium.
Who is sponsoring the NCT07621783 clinical trial?
NCT07621783 is sponsored by Imelda GI Clinical Research Center. The trial plans to enroll 100 participants.